MetaStat, Inc. (MTST)

0.0001 +0.0001 (+9,900.00%) At close: 01:47PM EDT

MetaStat, Inc.

27 Drydock Avenue
2nd Floor
Boston, MA 02210
United States
617-531-6500
https://www.metastat.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Douglas A. Hamilton B.Sc., M.B.A., MBA	CEO, President & Director	413.5k	N/A	1966
Mr. Frederick E. Pierce II	Vice President of Investor Relations	N/A	N/A	1962

Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.

Corporate governance

MetaStat, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.